Podnet na doplnenie - PP lieky a liečivá

Organisation: Union ZP, a.s

Created at: 17.04.2025

Processed at: 07.04.2026

Question

We have attributable items S01-01 Ranibizumab - Administration of Ranibizumab, intravitreal in the indication limitation and S01-02 Aflibercept - Administration of Aflibercept, intravitreal in the indication limitation in the KPP in the Medicines and Drug Products Annex. Other molecules categorised and used in practice - Brolucizumab, Faricimab and Dexamethasone - are administered, which will not be able to be reported as PPs and reimbursed or recorded as drug consumption in the transition to the DRG JHS.

Addition of the molecules in question to the PP Brolucizumab list - Administration of Brolucizumab, intravitreal in the indication restriction. Faricimab - Administration of Faricimab, intravitreal in the indication restriction. Dexamethasone - loc. intravitreal implant - Administration of Dexamethasone - intravitreal in the indication restriction. At the same time, move the above molecules, including Ranibizumab and Aflibercept, to Annex 7 of the PPJHS.

When switching to DRG JZS, it will not be possible to report the molecules in question as PP, reimburse and track consumption (reimbursement limit, MEA...).

Answer

That request was reconsidered and the Medical Review Panel proceeded to a vote, which is recorded in the minutes available here: https://www.cksdrg.sk/sk/dokumenty/571/Zápisy%20z%20rokovaní%20medicínsko-analytickej%20pracovnej%20skupiny%20s%20hlasovaniami.pdf

The proposed PPs have been approved and incorporated into the CMP with reimbursement type J.